cbdMD Therapeutics, cbdMD, Inc.’s newly formed research division, has finalized a research partnership with the University of Mississippi (UM) and its National Center for Natural Products Research.
UM is considered one of the leading cannabinoid research institutes in the United States. The research partnership aims to identify novel cannabinoids to be patented for therapeutic use in accordance with the U.S. and other governments regulatory standards. The studies will commence at the university in fall 2021.
The project’s major emphasis is to explore the chemistry and biology of minor cannabinoids beyond cannabidiol (CBD). The new cannabinoids will be evaluated for their receptor activity and the most promising will be studied for their safety and efficacy.
"This work raises the bar for the entire cannabinoid industry,” said Dr. Sibyl Swit, VP of scientific and regulatory affairs, cbdMD, Inc. “We are breaking new ground with the identification of novel cannabinoids and the exploration of their benefits for our consumers.”